↓ Skip to main content

ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development

Overview of attention for article published in Journal of Hematology & Oncology, November 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#40 of 1,121)
  • High Attention Score compared to outputs of the same age (94th percentile)
  • High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news
1 news outlet
blogs
2 blogs
twitter
2 tweeters
patent
3 patents

Citations

dimensions_citation
185 Dimensions

Readers on

mendeley
279 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
Published in
Journal of Hematology & Oncology, November 2015
DOI 10.1186/s13045-015-0224-3
Pubmed ID
Authors

Shundong Cang, Chaitanya Iragavarapu, John Savooji, Yongping Song, Delong Liu

Abstract

With the advent of new agents targeting CD20, Bruton's tyrosine kinase, and phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist than ever before. B-cell lymphoma-2 (BCL-2) plays a major role in cellular apoptosis and is a druggable target. Small molecule inhibitors of BCL-2 are in active clinical studies. ABT-199 (venetoclax, RG7601, GDC-0199) has been granted breakthrough designation by FDA for relapsed or refractory CLL with 17p deletion. In this review, we summarized the latest clinical development of ABT-199/venetoclax and other novel agents targeting the BCL-2 proteins.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 279 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 <1%
India 1 <1%
Unknown 277 99%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 65 23%
Student > Master 43 15%
Student > Bachelor 34 12%
Researcher 32 11%
Student > Doctoral Student 17 6%
Other 38 14%
Unknown 50 18%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 74 27%
Agricultural and Biological Sciences 41 15%
Medicine and Dentistry 38 14%
Pharmacology, Toxicology and Pharmaceutical Science 23 8%
Chemistry 20 7%
Other 26 9%
Unknown 57 20%

Attention Score in Context

This research output has an Altmetric Attention Score of 27. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 December 2021.
All research outputs
#1,136,734
of 21,742,867 outputs
Outputs from Journal of Hematology & Oncology
#40
of 1,121 outputs
Outputs of similar age
#24,067
of 404,053 outputs
Outputs of similar age from Journal of Hematology & Oncology
#3
of 84 outputs
Altmetric has tracked 21,742,867 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,121 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.4. This one has done particularly well, scoring higher than 96% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 404,053 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 84 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 97% of its contemporaries.